Cell Biology of Prostate Cancer and Molecular Targets -- Cell Biology of Prostate Cancer and Molecular Targets -- Hormone Therapy -- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer -- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer -- Androgens and Prostate Cancer -- Androgen Receptor Biology in Prostate Cancer -- Androgen Receptor Antagonists -- 5-Alpha Reductase Inhibitors in Prostate Cancer -- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer -- Androgen Deprivation Therapy -- Pharmacogenetics of the Androgen Metabolic Pathway -- Chemotherapy -- Mitoxantrone -- Docetaxel -- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer -- Platinum Agents in Prostate Cancer -- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer -- Microtubule Targeting Agents -- Angiogenesis -- Principles of Antiangiogenic Therapy -- Bevacizumab in Advanced Prostate Cancer -- Thalidomide and Analogs -- Investigational Angiogenesis Inhibitors -- Pharmacogenetics of Angiogenesis -- Bone Metastasis -- Pathophysiology of Prostate Cancer Bone Metastasis -- Radiopharmaceuticals -- Bisphosphonates for Prevention and Treatment of Bone Metastases -- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer -- Calcitriol and Vitamin D Analogs -- Immunotherapy -- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches -- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer -- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX -- CTLA-4 Blockade for Prostate Cancer Treatment -- Prevention -- Prostate Cancer Chemoprevention Strategies -- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk -- Inflammation as a Target in Prostate Cancer -- Drug Development -- Challenges for the Development of New Agents in Prostate Cancer -- FDA Approval of Prostate Cancer Treatments -- Applications of Proteomics in Prostate Cancer -- Erratum to: Docetaxel -- Erratum to: Docetaxel.

This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry